Trials / Recruiting
RecruitingNCT05891379
Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders
Effectiveness and Safety of Inebilizumab in the Acute Phase of Neuromyelitis Optica Spectrum Disorders-a Multicentric, Prospective, Real Word Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Xuanwu Hospital, Beijing · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is aimed to observe the effectiveness and safety of inebilizumab in the acute phase of neuromyelitis optica spectrum disorders.
Detailed description
This is a a multicentric, prospective, real word study of inebilizumab in NMOSD acute attack compared with oral immunosuppressant. A total of 50 patients will be enrolled at approximately 10 centers around China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inebilizumab | Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inelizumab is given during IVMP. |
| DRUG | oral immunosuppressant | Oral immunosuppressants (azathioprine or mycolate mofetil) are initiated during IVMP. |
Timeline
- Start date
- 2024-07-09
- Primary completion
- 2025-07-31
- Completion
- 2025-07-31
- First posted
- 2023-06-06
- Last updated
- 2024-09-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05891379. Inclusion in this directory is not an endorsement.